Aurobindo Pharma wins USFDA nod for two generics in 2026

Why Aurobindo Pharma stock is in focus

Aurobindo Pharma shares are set to remain in focus on April 20 after the company disclosed fresh product approvals from the US Food and Drug Administration (USFDA). The updates relate to two oral liquid formulations cleared for the US market. One is an over-the-counter cough product, while the other is a specialty therapy used in the management of urea cycle disorders. Both approvals add to the company’s US regulatory portfolio, a key monitorable for Indian generic drugmakers.

USFDA approval for OTC cough syrup: key details

The company received USFDA approval for Dextromethorphan Polistirex extended-release oral suspension (30 mg/5 mL, OTC). The formulation is described as bioequivalent and therapeutically equivalent to the reference listed drug Delsym Extended Release Oral Suspension. The reference product is marketed by RB Health (US) LLC. Aurobindo said the product is intended to provide temporary relief from cough caused by minor throat and bronchial irritation, including cough associated with the common cold or inhaled irritants. The product also targets suppression of the impulse to cough to help one get to sleep.

Where the cough suspension will be manufactured

Aurobindo said the cough suspension will be manufactured at Unit-IV of APL Healthcare, a wholly owned subsidiary. The planned commercial launch timeline shared in the update is Q2 FY27. In the company communication cited in the provided material, the product’s estimated market size was stated at US$ 138.0 million for the twelve months ending February 2026, based on Nielsen data.

Second US clearance: Glycerol Phenylbutyrate oral liquid

In a separate development, Aurobindo Pharma also received final USFDA approval to manufacture and market Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL). The product is described as bioequivalent and therapeutically equivalent to the reference listed drug Ravicti Oral Liquid, marketed by Horizon Therapeutics U.S. Holding LLC. The company said it plans an immediate launch in the market. Manufacturing for this product will be done at Unit-III of the company.

Indication and market sizing shared for Ravicti generic

The material notes that Glycerol Phenylbutyrate Oral Liquid is indicated as a nitrogen-binding agent for chronic management of patients with urea cycle disorders who cannot be managed by dietary protein restriction and amino acid supplementation alone. The estimated US market opportunity cited is US$ 50.2 million for the twelve months ending February 2026, based on IQVIA MAT data.

ANDA count: how these approvals add to Aurobindo’s US portfolio

The approval communications included updates on Aurobindo’s cumulative abbreviated new drug application (ANDA) approvals from the USFDA. For the cough suspension update, the company’s total ANDA approvals were stated as 580, comprising 557 final approvals and 23 tentative approvals. In the separate update on Glycerol Phenylbutyrate Oral Liquid, the total was stated as 579, comprising 556 final approvals and 23 tentative approvals. The difference reflects the sequencing of updates across dates in the provided material.

Key facts table

Stock trading snapshot cited in the material

One of the provided updates also carried BSE trading details around the time of the disclosure. It stated that Aurobindo Pharma was last trading at Rs 1,385.65 versus a previous close of Rs 1,386.10. The stock’s intraday high was Rs 1,394.10 and the intraday low was Rs 1,376.80. It also reported 24,210 shares traded across 1,587 trades, with net turnover of Rs 33,554,305.

Market impact: what investors typically track from such approvals

USFDA final approvals are closely watched because they enable commercial entry into the US generic market, subject to launch readiness and distribution decisions. In this case, Aurobindo provided different launch timelines for the two products, with one planned for Q2 FY27 and the other intended for immediate launch. The estimated market sizes cited, US$138.0 million for the OTC cough product and US$ 50.2 million for Glycerol Phenylbutyrate oral liquid, help frame the opportunity set referenced in the approvals. The updates also highlight Aurobindo’s use of multiple manufacturing sites, including a subsidiary facility, for US-facing products.

Why this matters for Aurobindo’s US strategy

The cough product is positioned in an OTC segment, where access is not limited by prescription and volumes can be broad, while the Glycerol Phenylbutyrate product addresses a specialised therapy area. Both approvals are described as bioequivalent and therapeutically equivalent to their respective reference listed drugs, a regulatory requirement for US generic approvals. The disclosures also underline the continuing addition to Aurobindo’s ANDA portfolio, which the company quantified in the updates.

What to watch next

Investors will typically watch for execution on the stated launch plans, including the immediate launch for Glycerol Phenylbutyrate oral liquid and the Q2 FY27 timing for the OTC cough suspension. Any further company disclosures around commercial rollout, supply readiness, or distribution plans could provide additional clarity on near-term contribution.